Abstract
Resistance to Ceftazidime-Avibactam in Enterobacter cloacae is poorly understood. Whole genome sequencing identified 6 variants in isolates collected from a patient before and after acquiring Ceftazidime-Avibactam resistance. This included a Phe396Leu mutation in acrB, a component of the AcrAB-TolC efflux pump, possibly mediating enhanced efflux of Ceftazidime and/ or Avibactam.
Keywords:
Ceftazidime-Avibactam resistance; Enterobacter cloacae; efflux pumps; whole genome sequencing.
Copyright © 2021 Elsevier Inc. All rights reserved.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Azabicyclo Compounds / pharmacology
-
Azabicyclo Compounds / therapeutic use*
-
Bacterial Proteins / genetics
-
Ceftazidime / pharmacology
-
Ceftazidime / therapeutic use*
-
Drug Combinations
-
Drug Resistance, Multiple, Bacterial / drug effects
-
Drug Resistance, Multiple, Bacterial / genetics*
-
Enterobacter cloacae / drug effects
-
Enterobacter cloacae / genetics*
-
Enterobacter cloacae / isolation & purification
-
Enterobacteriaceae Infections / drug therapy
-
Enterobacteriaceae Infections / microbiology*
-
Genome, Bacterial / genetics
-
Genomics
-
Humans
-
Male
-
Membrane Transport Proteins / genetics
-
Microbial Sensitivity Tests
-
Middle Aged
-
Mutation
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Bacterial Proteins
-
Drug Combinations
-
Membrane Transport Proteins
-
avibactam, ceftazidime drug combination
-
Ceftazidime